Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.590-590
- Shah, Payal Deepak
- Chandarlapaty, Sarat
- Dickler, Maura N.
- Ulaner, Gary
- Zamora, Stephen James
- Sterlin, Valentina
- Iasonos, Alexia
- Coughlin, Christina Marie
- Morozov, Alex
- Ero, Joy
- Rosen, Neal
- Gilewski, Teresa
- Fornier, Monica Nancy
- Sklarin, Nancy T.
- Berger, Michael F.
- Moynahan, Mary Ellen
- Hudis, Clifford A.
- Baselga, Jose
- Modi, Shanu
2015
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Shah, Payal Deepak
- Chandarlapaty, Sarat
- Dickler, Maura N.
- Ulaner, Gary
- Zamora, Stephen James
- Sterlin, Valentina
- Iasonos, Alexia
- Coughlin, Christina Marie
- Morozov, Alex
- Ero, Joy
- Rosen, Neal
- Gilewski, Teresa
- Fornier, Monica Nancy
- Sklarin, Nancy T.
- Berger, Michael F.
- Moynahan, Mary Ellen
- Hudis, Clifford A.
- Baselga, Jose
- Modi, Shanu
- Titel
- Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)
- Ist Teil von
- Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.590-590
- Erscheinungsjahr
- 2015
- Quelle
- EZB Electronic Journals Library
- Beschreibungen/Notizen
- Abstract only
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0732-183XeISSN: 1527-7755DOI: 10.1200/jco.2015.33.15_suppl.590Titel-ID: cdi_crossref_primary_10_1200_jco_2015_33_15_suppl_590
- Format
- –